Has Eugenio Rivera Rios, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,430 in general payments to Eugenio Rivera Rios, MD across 124 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Eugenio Rivera Rios, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Eugenio Rivera Rios, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Eugenio Rivera Rios, MD

Pulmonary Disease · Ponce, PRNPI 1689642134

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 51.5% of the total. 2024 is the largest year on record at $954, 2.5 times the $387 reported in 2019.

$3,430in general payments, 2019–2025

Across 124 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
GSK$1K
Sanofi$146
Boehringer Ingelheim$122
Genentech USA, Inc.$72
Amgen$39
plus $48 from 2 others

What the payments were for

Food & beverage$3,430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	72	$1,767
GSK	36	$1,236
Sanofi	6	$146
Boehringer Ingelheim	3	$122
Genentech USA, Inc.	3	$72
Amgen	2	$39
Jazz Pharmaceuticals Inc.	1	$33
PBG Puerto Rico LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,430 in reported general payments places this provider in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$2,576

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fasenra PenBenralizumab	49	$281,653
FasenraBenralizumab	34	$196,504
NucalaMepolizumab	14	$49,133
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	70	$46,840
Stiolto RespimatTiotropium Br/Olodaterol Hcl	65	$33,138
Spiriva RespimatTiotropium Bromide	61	$32,517
Fluticasone Propionate HfaFluticasone Propionate	85	$31,662
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	78	$23,753
Breo ElliptaFluticasone/Vilanterol	50	$22,732
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	41	$21,424
Wixela InhubFluticasone Propion/Salmeterol	79	$15,314
Albuterol Sulfate HfaAlbuterol Sulfate	254	$11,236
SymbicortBudesonide/Formoterol Fumarate	41	$10,637
Breztri AerosphereBudesonide/Glycopyr/Formoterol	12	$7,946
Arnuity ElliptaFluticasone Furoate	13	$3,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFasenra, Symbicort, Breztri Aerosphere	$1,767	$215,08887 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta	$1,236	$143,881188 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat	$122	$65,655126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Ponce

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →